Zura Bio Limited Class A Ordinary Shares Stock News

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Forms Scientific Advisory Board with Prominent Specialists.

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and

The consensus price target hints at a 235.2% upside potential for Zura Bio Limited (ZURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and

Penny stocks to buy carry a considerable amount of risk. That's why we include the disclaimer at the tail-end of this article.

The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Zura Bio Limited (ZURA). While the effectiveness of this highly sought-after metric is questionable,

Zura Bio Limited (ZURA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

As tech giants and other sector leaders report their most recent quarterly results, one might expect notable insider purchases to be scarce.

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflamm

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and i

HENDERSON, Nev--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and in

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio announces participation at three March conferences.

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio today announced participation at several upcoming conferences in February.

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Announces Appointment of Robert Lisicki as President and Dr. Kiran Nistala as CMO.